Clinical Trials Logo

Clinical Trial Summary

CC-90011-AML-002 is a Phase 1/2, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently with Venetoclax and Azacitidine. This study will include 3 parts: a dose escalation part in R/R AML, a dose escalation part in ndAML (treatment-naïve participants with AML who are ≥ 75 years of age or are ≥ 18 to 74 years of age and otherwise not eligible for intensive induction chemotherapy), and a randomized dose expansion part in ndAML of Venetoclax and Azacitidine with or without CC-90011.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04748848
Study type Interventional
Source Celgene
Contact
Status Terminated
Phase Phase 1
Start date October 14, 2021
Completion date March 9, 2022

See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT00233909 - A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT04039100 - Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease N/A
Recruiting NCT03600558 - Efficacy of FLAG Regimen for the Treatment of Patients With AML
Completed NCT02538965 - A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT02333838 - Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies Phase 2
Completed NCT01061177 - Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Phase 4
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Terminated NCT02370888 - Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease Phase 1
Recruiting NCT05805605 - Allo HSCT Using RIC and PTCy for Hematological Diseases Phase 2
Recruiting NCT03080922 - High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML Phase 1/Phase 2
Completed NCT01392989 - Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Phase 2
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Completed NCT00451997 - Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes Phase 2
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Recruiting NCT05458258 - Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
Completed NCT00065143 - Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Phase 2
Recruiting NCT04789655 - Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Withdrawn NCT04406207 - Endogenous Retroviruses in Acute Myeloid Leukemia